Molecular Partners and Orano Med Team Up for Alpha Radiotherapies for Cancer (MOLN: NASDAQ)


cancer patient and modern treatment

Xesai

  • Biotechnology company in clinical phase Molecular Partners (NASDAQ:CLOUD) and Orano Med, a radiopharmaceutical company in the clinical phase expand their strategic collaboration.
  • The terms of the new agreement include the development of six additional targeted alpha therapeutic candidates, now representing a total of ten potential candidates.



Source link

  • Related Posts

    Stocks to watch on Tuesday: MicroStrategy, Angi, BP, Trump Media

    Stocks to watch on Tuesday: MicroStrategy, Angi, BP, Trump Media Source link

    British pharma giant GSK to acquire US drug developer IDRx in $1.15 billion deal

    The biopharmaceutical company’s drug in development is designed to treat gastrointestinal stromal tumors (GIST). Read More Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *